First-in-man study of simvastatin-eluting stent in de novo coronary lesions: The SIMVASTENT study

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1109-1114

  do Canto Zago, Alexandre ^a   Matte, Bruno S ^a   Reginato, Luciana ^a   Iturry Yamamoto, Germán ^a   Krepsky, Ana ^a   Bergoli, Luiz Carlos C ^a   Balvedi, Julise ^a   Raudales, José C ^a   Saadi, Eduardo K ^a   Zago, Alcides J ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Drug eluting stent; Intravascular ultrasound; Simvastatin; Statins; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; SIMVASTATIN; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY LESION; ARTICLE; BARE METAL STENT; BLOOD VESSEL DIAMETER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LESION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; LOADING DRUG DOSE; MALE; NEOINTIMA; PROSPECTIVE STUDY; RESTENOSIS; THORAX PAIN;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOINTIMA; SIMVASTATIN; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84860188115     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1125     Document Type: Article

References (36)

1. Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J. Effects of statins on vascular structure and function: A systematic review. Am J Med 2004; 117: 775-790.
2. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213-220.
3. Chen Z, Fukutomi T, Zago AC, Ehlers R, Detmers PA, Wright SD, et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 2002; 106: 20-23.
4. Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
5. Indolfi C, Curcio A, Chiariello M. Simvastatin reduces neointimal thickening after experimental angioplasty. Circulation 2003; 107: e25.
6. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35: 214-221.
7. Miyauchi K, Kasai T, Yokayama T, Aihara K, Kurata T, Kajimoto K, et al. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J 2008; 72: 832-838.
8. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000; 85: 962-968.
9. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004; 174: 253-259.
10. Casani L, Juan O, Serra A, Duocastella L, Molina M, Garcia-Rafanell J, et al. A new DES with anti-inflammatory and antiproliferative activity reduces in-stent restenosis. Eur Heart J 2009; 30 (Abstract Supplement): 532.
11. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005; 68: 483-492.
12. Kaneko H, Kijima M. Role of bare-metal stents for left main coronary artery disease in the era of drug-eluting stents. Circ J 2011; 75: 1243-1249.
13. Kadota K, Mitsudo K. Percutaneous coronary intervention with drugeluting stent for unprotected left main trunk disease: Safety and efficacy compared with bare metal stent. Circ J 2011; 75: 1250-1254.
14. Hoye A, van der Giessen WJ. New approaches to ostial and bifurcation lesions. J Interv Cardiol 2004; 6: 397-403.
15. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
17. Brara PS, Moussavian M, Grise MA, Reilly JP, Fernandez M, Schatz RA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation 2003; 107: 1722-1724.
18. Kothwala D, Raval A, Choubey A, Engineer C, Kotadia H. Paclitaxel drug delivery from cardiovascular stent. Trends Biomater Artif Organs 2006; 19: 88-92.
19. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: Six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
20. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1: 58-65.
21. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
22. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
23. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
24. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005; 1: 157-164.
25. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxeleluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
26. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
27. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimuseluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447.
28. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, et al. Intravascular ultrasound results from the ENDEAVOR IV trial: Randomized comparison between zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009; 2: 779-784.
29. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.
30. Shimohama T, Ako J, Yamasaki M, Otake H, Tsujino I, Hasegawa T, et al. SPIRIT III Japan versus SPIRIT III USA: A comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol 2010; 106: 13-17.
31. Waseda K, Ako J, Yamasaki M, Koizumi T, Ormiston J, Worthley SG, et al. Short-and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer: Results from the RESOLUTE trial. Circ J 2010; 74: 2097-2102.
32. Costa JR Jr, Abizaid A, Feres F, Costa R, Seixas AC, Maia F, et al. EXCELLA first-in-man (FIM) study: Safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention 2008; 4: 53-58.
33. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease: The COURAGE Trial. N Engl J Med 2007; 356: 1503-1516.
34. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimuscoated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-195.
35. Curcio A, Torella S, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting. Circ J 2011; 75: 1287-1296.
36. Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, Surace FC, et al. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am J Physiol Heart Circ Physiol 2007; 292: H2935-H2943.